Clinical trials: Localized Cancer, open to volunteers
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Neurofibromatosis Type 1, Neurofibroma
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
Background: Neurofibromatosis 1 (NF1) is a disease that causes tumors to grow along the nerves. These include plexiform neurofibromas (pNF) and cutaneous neurofibromas (cNF). Both pNF and cNF can be visible to other people.
- Trial name
- NCT06880991
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery
The purpose of the study is to evaluate how precise the SAVI Scout MD is and how easy it is for surgeons to use during surgery. The SAVI Scout MD system uses tiny radar reflectors instead of wires, can be placed days or weeks…
- Trial name
- NCT07686250
- Testing
- SAVI Scout MD system
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Kidney Neoplasm
Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving…
- Trial name
- K3 (NCT07234409)
- Testing
- STANDARD FLANK APPROACH, Supine anterior retroperitoneal approach (SARA).
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Niguarda Hospital
Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
- Trial name
- SACRO (NCT02986516)
- Testing
- Randomized Cohort, Prospective cohort
- Where
- 28 sites in Austria, Germany and 8 more
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
Prostate Cancer
Pilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL)
This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated/de-escalated dose directed by MRI) 5 fraction SBRT to the…
- Trial name
- DESTINATION-MR (NCT06177093)
- Testing
- MR Linac delivered Radiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer, Localized Prostate Carcinoma
PSMA-Guided Ablation of the Prostate
The goal of this phase 2 multicenter randomized controlled trial is to study the accuracy of second generation prostate specific membrane antigen (PSMA) positron emission tomography (PET; utilizing 18F-PSMA-1007) compared to…
- Trial name
- P-GAP (NCT06003556)
- Testing
- PSMA-1007 Positron Emission Tomography (PET) scan
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Pancreatic Adenocarcinoma
The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer
The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma.
- Trial name
- NCT05752812
- Where
- Austria
- Volunteers
- 1,500 people
- Sponsor
- Medical University of Vienna
Breast Neoplasms, Hormone Receptor-Positive Breast Cancer
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
Why is this study being done? Many patients with a type of breast cancer (called HR-positive) take a medicine called Abemaciclib.
- Conditions
- Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Abemaciclib, Abemaciclib-related Diarrhea
- Trial name
- NCT07264998
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hubei Cancer Hospital
Breast Cancer
Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy
Some types of localised breast cancer, including stage II and III, HER2 positive (Human Epidermal Growth Factor Receptor) or triple negative cancers are treated with primary or neoadjuvant chemotherapy prior to surgical treatment…
- Trial name
- CERePred (NCT06299202)
- Testing
- Diagnostic test
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease.
- Trial name
- NCT04549688
- Testing
- high-intensity focused ultrasound, HIFU
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- The Hospital of Vestfold
Prostate Cancer
Ablative Therapy in the Management of Prostate Cancer
The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal…
- Trial name
- NCT03492424
- Testing
- cryotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer, Prostate Neoplasm
Effectiveness of Focal Therapy in Men With Prostate Cancer
In the Netherlands, most men with prostate cancer (PCa) are treated with radical whole-gland treatment, i.e. prostatectomy or radiotherapy.
- Trial name
- ENFORCE (NCT06223295)
- Testing
- Focal therapy, Usual care
- Where
- 5 sites in Netherlands
- Volunteers
- 356 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Understanding of Genetics by Men at Risk for Prostate Cancer
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions.
- Trial name
- NCT04550845
- Testing
- Focus group analyses
- Where
- 3 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
- Trial name
- HEATWAVE (NCT06067269)
- Testing
- Apalutamide, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Localized Prostate Adenocarcinoma
Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer
Hip replacements and prostate cancer are independently and both together increasing prevalent in the aging population. In the United States, the prevalence of hip prostheses among men was 1.1 million in 20101, with approximately…
- Trial name
- HIP-PRO (NCT07042256)
- Testing
- Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- University of Zurich
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Localized Prostate Cancer
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help.
- Trial name
- NCT05155046
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Adenocarcinoma
NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101
Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease.
- Trial name
- FLUOPANC-II (NCT05984810)
- Testing
- Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center